Effect of low-density lipoprotein apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia

被引:13
|
作者
Maugeais, C
Ouguerram, K
Frénais, R
Maugère, P
Charbonnel, B
Magot, T
Krempf, M [1 ]
机构
[1] Hotel Dieu, Clin Endocrinol, F-44093 Nantes 01, France
[2] Hotel Dieu, Ctr Rech Nute Humaine, F-44093 Nantes 01, France
来源
关键词
D O I
10.1210/jc.86.4.1679
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The acute reduction of low-density lipoprotein (LDL) cholesterol obtained by LDL-apheresis allows the role of the high level of circulating LDL on lipoprotein metabolism in heterozygous familial hypercholesterolemia (heterozygous FH) to he addressed. We studied apolipoprotein B (apoB) kinetics in five heterozygous FH patients before and the day after an apheresis treatment using endogenous labeling with [(2)H(3)]leucine. Compared with younger control subjects, heterozygous FH patients before apheresis showed a significant decrease in the fractional catabolic rate of LDL (0.24 +/- 0.08 vs. 0.65 +/- 0.22 day(-1); P < 0.01), and LDL production was increased in heterozygous FH patients (18.9 +/- 7.0 vs. 9.9 +/- 4.2 mg/kg.day; P < 0.05). The modeling of postapheresis apoB kinetics was performed using a nonsteady state condition, taking into account the changing pool size of very low density lipoprotein (VLDL), intermediate density lipoprotein, and LDL apoB. The postapheresis kinetic parameters did not show statistical differences compared with preapheresis parameters in heterozygous FH patients; however, a trend for increases in fractional catabolic rate of LDL (0.24 +/- 0.08 vs. 0.35 +/- 0.09 day(-1); P = 0.067) and the production of VLDL (13.7 +/- 8.3 vs. 21.9 +/- 1.6 mg/ kg day; P = 0.076) was observed. These results suggested that the marked decrease in plasma LDL obtained a short time after LDL-apheresis is able to stimulate LDL receptor activity and VLDL production in heterozygous FH.
引用
收藏
页码:1679 / 1686
页数:8
相关论文
共 50 条
  • [31] Efficacy of Low-Density Lipoprotein Cholesterol Apheresis in the Treatment of Familial Hypercholesterolemia: Single Center Experience
    Hacisahinogullari, Hulya
    Oyman, Gamze Bilik
    Mutlu, Ummu
    Dadin, Senem
    Yalin, Gulsah Y.
    Soyluk, Ozlem
    Gul, Nurdan
    Besisik, Sevgi Kalayoglu
    Satman, Ilhan
    Karsidag, Kubilay
    Uzum, Ayse Kubat
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2025, 133 (02) : 92 - 97
  • [32] The role of low-density lipoprotein apheresis in the treatment of hypercholesterolemia and arteriosclerosis
    Koga, N
    THERAPEUTIC APHERESIS, 2001, 5 (04): : 219 - 219
  • [33] ABNORMAL LOW-DENSITY LIPOPROTEIN COMPOSITION IN FAMILIAL HYPERCHOLESTEROLEMIA
    JADHAV, AV
    THOMPSON, GR
    CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1977, 52 (02): : P18 - P19
  • [34] A rare low-density lipoprotein receptor (LDLR) gene mutation associated with heterozygous familial hypercholesterolemia
    Ortiz Espejo, M.
    Batanero Maguregui, R.
    Montalban Carrasco, C.
    Piedra Leon, M.
    Garcia Sardina, R.
    Esparza Del Valle, C.
    Moyano Martinez, A.
    Diez Espiga, S.
    Iturralde Ros, M.
    CLINICA CHIMICA ACTA, 2019, 493 : S205 - S206
  • [35] The effect of growth hormone on low-density lipoprotein cholesterol and lipoprotein(a) levels in familial hypercholesterolemia
    Tonstad, S
    Sundt, E
    Ose, L
    Hagve, TA
    Fruchart, JC
    Bard, JM
    Eden, S
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (11): : 1415 - 1421
  • [36] Low Density Lipoprotein Apheresis in Pediatric Patients With Homozygous Familial Hypercholesterolemia
    Coker, Mahmut
    Ucar, Sema Kalkan
    Simsek, Damla Goksen
    Darcan, Sukran
    Bak, Mustafa
    Can, Sule
    THERAPEUTIC APHERESIS AND DIALYSIS, 2009, 13 (02) : 121 - 128
  • [37] MEMBRANE LOW-DENSITY-LIPOPROTEIN APHERESIS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    VONBAEYER, H
    SCHWERDTFEGER, R
    KOCHINKE, F
    SCHWANER, I
    ARTIFICIAL ORGANS, 1986, 10 (01) : 71 - 71
  • [38] The Low-Density Lipoprotein Receptor Genotype Is a Significant Determinant of the Rebound in Low-Density Lipoprotein Cholesterol Concentration After Lipoprotein Apheresis Among Patients With Homozygous Familial Hypercholesterolemia
    Drouin-Chartier, Jean-Philippe
    Tremblay, Andre J.
    Bergeron, Jean
    Lamarche, Benoit
    Couture, Patrick
    CIRCULATION, 2017, 136 (09) : 880 - 882
  • [39] Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report
    Zenti, M. G.
    Stefanutti, C.
    Sanga, V.
    Altomari, A.
    Fabris, A.
    Dauriz, M.
    Bonora, E.
    JOURNAL OF CLINICAL APHERESIS, 2018, 33 (04) : 546 - 550
  • [40] Effect of Low-Density Lipoprotein Apheresis on Quality of Life in Patients with Diabetes, Proteinuria, and Hypercholesterolemia
    Hara, Akinori
    Wada, Takashi
    Muso, Eri
    Maruyama, Shoichi
    Kato, Sawako
    Furuichi, Kengo
    Yoshimura, Kenichi
    Toyama, Tadashi
    Sakai, Norihiko
    Suzuki, Hiroyuki
    Tsukamoto, Tatsuo
    Miyazaki, Mariko
    Sato, Eiichi
    Abe, Masanori
    Shibagaki, Yugo
    Narita, Ichiei
    Goto, Shin
    Sakamaki, Yuichi
    Yokoyama, Hitoshi
    Mori, Noriko
    Tanaka, Satoshi
    Yuzawa, Yukio
    Hasegawa, Midori
    Matsubara, Takeshi
    Wada, Jun
    Tanabe, Katsuyuki
    Masutani, Kosuke
    Abe, Yasuhiro
    Tsuruya, Kazuhiko
    Fujimoto, Shouichi
    Iwatsubo, Shuji
    Tsuda, Akihiro
    Suzuki, Hitoshi
    Kasuno, Kenji
    Terada, Yoshio
    Nakata, Takeshi
    Iino, Noriaki
    Sofue, Tadashi
    Miyata, Hitomi
    Nakano, Toshiaki
    Ohtake, Takayasu
    Kobayashi, Shuzo
    BLOOD PURIFICATION, 2023, 52 (04) : 373 - 381